Renaissance Capital logo

IPO in sight: Biolight Life Sciences files for a $10 million IPO

February 10, 2016

BioLight Life Sciences, which is developing therapies and equipment for treating glaucoma, dry eye and AMD, filed on Wednesday with the SEC to raise up to $10 million in an initial public offering.

The currently is listed on the Tel Aviv Stock Exchange under the ticker BOLT. However, its offering will be excluded from our IPO stats because it does not meet our market cap cutoff.

The Tel Aviv, Israel-based company was founded in 2005 plans to list on the Nasdaq under the symbol BOLT. Feltl and Company and Rodman & Renshaw are the joint bookrunners on the deal. No pricing terms were disclosed.